Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Alzheimer's & Dementia : the Journal of the Alzheimer's Association Année : 2019

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

1 University of Oxford
2 Universität zu Lübeck = University of Lübeck [Lübeck]
3 CAU - Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel
4 King‘s College London
5 GU - Göteborgs Universitet = University of Gothenburg
6 Cardiff University
7 Maastricht University [Maastricht]
8 VU University Medical Center [Amsterdam]
9 University Hospitals Leuven [Leuven]
10 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
11 VUB - Vrije Universiteit Brussel
12 UA - University of Antwerp
13 UNIGE - Université de Genève = University of Geneva
14 Istituto Centro San Giovanni di Dio Fatebenefratelli
15 INS - Institut de Neurosciences des Systèmes
16 APHM - Assistance Publique - Hôpitaux de Marseille
17 GSK - GlaxoSmithKline [Stevenage, UK]
18 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
19 Université de Lille
20 IDIBAPS - Hospital Clinic
21 UPF - Universitat Pompeu Fabra [Barcelona]
22 Sahlgrenska Academy at University of Gothenburg [Göteborg]
23 AHEPA University General Hospital [Thessaloniki]
24 Hospital de la Santa Creu i Sant Pau
25 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
26 HUG - Geneva University Hospital
27 Center for Research and Advanced Therapies CITA-Alzheimer Foundation [San Sebastián]
28 Copenhagen University Hospital
29 Amsterdam UMC - Amsterdam University Medical Center
30 VU - Vrije Universiteit Amsterdam [Amsterdam]
31 Karolinska Institutet [Stockholm]
32 Örebro University
33 Universität Heidelberg [Heidelberg] = Heidelberg University
34 Institutes of Neurology and Healthcare Engineering, UCL, London
35 Sahlgrenska University Hospital [Gothenburg]
36 UCL Queen Square Institute of Neurology
37 Janssen Research & Development
38 UiO - University of Oslo
Liu Shi
  • Fonction : Auteur
Alberto Lleó
Daniel Alcolea

Résumé

Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. Results: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. Discussion: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.

Domaines

Neurosciences

Dates et versions

hal-03598023 , version 1 (04-03-2022)

Identifiants

Citer

Liu Shi, Sarah Westwood, Alison Baird, Laura Winchester, Valerija Dobricic, et al.. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 2019, 15 (11), pp.1478-1488. ⟨10.1016/j.jalz.2019.06.4951⟩. ⟨hal-03598023⟩
28 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More